Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5775)
  3. Review (420)
  4. Editorial (194)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (61)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13268)
  2. Center for Hematologic Malignancies (10604)
  3. GSK Faculty (4481)
  4. Adult Leukemia (3669)
  5. Bone Marrow Transplant (2847)
  6. Lymphoma (2704)

More Groups

People
  1. Sergio Giralt (1068)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (330)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3528)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (329)
  5. Haematologica (291)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3803)
  2. Elsevier Inc. (1529)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13369)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Ahsan, A.; Mantis, C.; Luo, X.; Zhang, C. C.; Valdes, C. R.; Voorhees, P. M.; D'Souza, A.; Chung, A.; Tuchman, S.; Safah, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9
    Meeting Abstract

    Sborov, D. W.; Pawlyn, C.; Ishida, T.; Huang, J. S. Y.; Benjamin, R.; Iida, S.; Popat, R.; Kuroda, J.; Pianko, M. J.; Ramakrishnan, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma
    Meeting Abstract

    Wang, Y.; Larson, M. C.; Kumar, A.; Hill, B. T.; Bond, D. A.; Kahl, B. S.; Danilov, A. V.; Merryman, R.; Grover, N. S.; Tun, A. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC
    Meeting Abstract

    Deininger, M.; Apperley, J.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; de Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J. K.; Maness, L. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL)
    Meeting Abstract

    Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M. K.; Lunning, M. A.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors
    Meeting Abstract

    Aggen, D. H.; McKean, M.; Hoffman-Censits, J. H.; Lakhani, N. J.; Alhalabi, O.; Guancial, E. A.; Bashir, B.; Bowman, I. A.; Tan, A.; Lingaraj, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study
    Meeting Abstract

    Jabbour, E.; Tholouli, E.; Sandhu, K. S.; Shaughnessy, P.; Barba, P.; Guerreiro, M.; Yallop, D.; Logan, A.; Abedi, M.; Lao-Sirieix, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Impact of bridging therapy (BT) on lisocabtagene maraleucel (liso-cel) treatment in patients (pt) with R/R follicular lymphoma (FL)
    Meeting Abstract

    Reguera, J. L.; Garcia-Sancho, A. M.; Kuruvilla, J.; Izutsu, K.; Barbui, A. M.; Peter, B.; Mielke, S.; Palomba, M. L.; Cartron, G.; Ghesquieres, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial
    Meeting Abstract

    D'Angelo, S. P.; Furness, A. J. S.; Thistlethwaite, F.; Burgess, M. A.; Riedel, R. F.; Haanen, J.; Noujaim, J.; Chalmers, A. W.; Pousa, Alpo; Chugh, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM)
    Meeting Abstract

    Ikeguchi, A.; Sato, T.; Butler, M. O.; Carvajal, R. D.; Sacco, J. J.; Shoushtari, A. N.; Hassel, J. C.; Nathan, P. D.; Piulats, J. M.; Johnson, D. B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save